Novartis Korea to resubmit world data for Sebivo.

Novartis Korea was embarrassed at encountering the NHI price approval rejection for Sebivo (telbivudine), a chronic B hepatitis therapy on July 12, and CEO Andrin Oswald of Novartis Korea regretted to say "No chances for us to hear from the government why the product price was high nor to present our explanatory letters to them. We might have considered the price negotiation if problems arose ...